https://scholars.lib.ntu.edu.tw/handle/123456789/630403
標題: | Peginterferon alfa-2a plus Weight-Based or Flat-Dose Ribavirin for Treatment-Naïve Hepatitis C Virus Genotype 2 Rapid Responders: A Randomized Trial | 作者: | CHEN-HUA LIU Huang, Chung-Feng CHUN-JEN LIU Dai, Chia-Yen Huang, Jee-Fu JOU-WEI LIN Liang, Cheng-Chao Yang, Sheng-Shun CHIH-HUNG LIN TUNG-HUNG SU HUNG-CHIH YANG PEI-JER CHEN DING-SHINN CHEN Chuang, Wan-Long JIA-HORNG KAO Yu, Ming-Lung |
關鍵字: | 28B GENETIC POLYMORPHISMS; TREATMENT DURATION; VIROLOGICAL RESPONSE; COMBINATION THERAPY; ANTIVIRAL TREATMENT; HCV GENOTYPE-2; ASIAN PATIENTS; SOFOSBUVIR; INFECTION; FIBROSIS | 公開日期: | 15-十月-2015 | 出版社: | NATURE PUBLISHING GROUP | 卷: | 5 | 期: | 1 | 起(迄)頁: | 15255 | 來源出版物: | Scientific reports | 摘要: | The impact of ribavirin (RBV) dosage on sustained virologic response (SVR) rates remains elusive in hepatitis C virus genotype 2 (HCV-2) rapid responders receiving 16 weeks of peginterferon (Peg-IFN) plus RBV. Treatment-naïve HCV-2 patients with rapid virologic response (RVR) received Peg-IFN alfa-2a 180 μg/week plus weight-based RBV (1,000 or 1,200 mg/day; cut-off body weight: 75 kg) for 6 weeks, and then randomly received Peg-IFN alfa-2a 180 μg/week plus weight-based (1,000 or 1,200 mg/day; n = 247) or flat-dose (800 mg/day; n = 246) RBV for additional 10 weeks. The primary endpoint was SVR24. Patients receiving weight-based and flat-dose RBV therapies had comparable SVR24 rates (93.5% versus 91.9%, P = 0.49). The risk differences (RDs) of SVR24 receiving weight-based and flat-dose RBV arms were 7.1% [95% CI: 0.7% to 13.6%] in males, and -5.8% [95% CI: -12.1% to 0.5%] in females (interaction P = 0.01). The SVR24 rate was higher in males receiving ≥13 mg/kg/day than those receiving <13 mg/kg/day (96.3% versus 85.1%, P = 0.001). In conclusion, Peg-IFN alfa-2a plus weight-based or flat-dose RBV for 16 weeks provides comparable SVR24 rates in treatment-naïve HCV-2 rapid responders. However, males should receive weight-based RBV to achieve a high SVR24 rate. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/630403 | ISSN: | 2045-2322 | DOI: | 10.1038/srep15255 |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。